Cholera is an acute level of diarrheal disease that has the ability to kill the diseased person within hours, if untreated. This infectious disease causes severe watery diarrhea, leading to acute dehydration. Although awareness has grown considerably over the past two decades, cholera outbreaks are still common and lead to serious problems in a number of low- and middle-income countries.
According to a 2015 publication in PLOS Neglected Tropical Diseases, it has been estimated that each year, there are about 1.3-4.0 million cases of cholera, and 21,000-143,000 cholera-related deaths, worldwide. There are around 70 endemic countries, globally, that suffer from cholera, currently. Companies, in recent years, have targeted the development of vaccines and biologics to curb the disease. The vaccines with oral and injectable routes of administration have been successful in conjugated or lyophilized forms.
This report by Mordor Intelligence provides extensive insights into the current scenario and growth prospects of the market studied. Detailed graphical representations of the pipeline landscape, based on various phases, and the status of clinical trials, across major regions of the world, are given, with data obtained from multiple sources. The report also comprises a list of key sponsors with pipeline products for the concerned market.
The report will cover analysis on trails and information on key sponsors, companies, and researchers.
Our data collection team builds scientific research models, based on data sourced from various internal databases, primary and secondary researches, and our in-house team of research experts. The pipeline assessment reports are generated based on information procured from various stakeholders, such as sponsors, clinical trial organizations, pharmaceutical companies, government bodies, trade agencies, industry journals, scientific literature databases, investor reports, press release statements, and several other sources. The data generated using secondary research and primary research is validated through discussions with industry KOL’s and C-suite executives. The data presented in the reports is continuously updated to incorporate the most relevant and authentic information to our clients.
2. Research Methodology
3. Disease Epidemiology and Trends
4. Healthcare Expenditure and R&D Trends
5. Executive Summary
6. Clinical Trials Segmentation by Phase
6.1 Phase-III Product Candidates
6.2 Phase-II Product Candidates
6.3 Phase-I Product Candidates
7. Clinical Trials, Segmentation by Status
8. Pipeline Therapeutic Assessment (Infographic Charts and a Brief Description)
8.1. By Clinical Phase and Molecule Type
8.2. By Clinical Phase and Route of Administration
8.3 By Sponsor/Collaborator/Institutions
8.4 By Geography
9. Market Updates
10. Key Sponsor Profiles
11. Sources and Disclaimer
12. About Mordor Intelligence